Technology | November 17, 2010

Eplerenone Reduces Mortality Risk in Mild Heart Failure Patients

November 17, 2010 – Chronic heart failure patients treated with eplerenone (Inspra) experienced a significant reduction in risk of cardiovascular death or heart failure hospitalizations. The data comes from the EMPHASIS-HF trial, which compared Pfizer’s drug to placebo and standard therapy in patients with mild symptoms.

Results were presented at the American Heart Association’s Scientific Sessions and published online in the New England Journal of Medicine.

The trial demonstrated a 37 percent relative risk reduction for the eplerenone group for death from cardiovascular causes or heart failure hospitalization. Additionally, there were significant reductions in all-cause mortality, cardiovascular mortality, all-cause hospitalization and heart failure hospitalization.

"It is encouraging to see a clinical trial deliver results that are sufficiently strong to meet strict pre-defined stopping criteria,” said Faiez Zannad, M.D., professor of therapeutics and cardiologist at the University Hospital of the Henri Poincare University of Nancy, France and co-chair of the EMPHASIS-HF steering committee. “Patients such as those enrolled in EMPHASIS-HF typically have a poor prognosis and today's results should therefore provide real encouragement for doctors and patients alike."

No new safety information emerged as a result of this study. As expected, there was a higher incidence of hyperkalemia (elevated potassium) among patients assigned to eplerenone compared to placebo. However, hypokalemia (low potassium) was lower in the eplerenone group.

Eplerenone (Inspra) is a steroid nucleus-based mineralcorticoid receptor (MR) antagonist with a higher degree of selectivity than spironolactone.

For more information: www.pfizer.com

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init